Ispecimen Stock Today

ISPC Stock  USD 1.34  0.07  5.51%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Very High

 
High
 
Low
ISpecimen is trading at 1.34 as of the 16th of March 2025, a 5.51 percent increase since the beginning of the trading day. The stock's open price was 1.27. ISpecimen has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
17th of June 2021
Category
Healthcare
Classification
Health Care
iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. The company has 962.64 K outstanding shares of which 29.56 K shares are currently shorted by private and institutional investors with about 0.1 trading days to cover. More on iSpecimen

Moving together with ISpecimen Stock

  0.64VRCA Verrica PharmaceuticalsPairCorr
  0.78ENVB Enveric Biosciences Earnings Call Next WeekPairCorr

Moving against ISpecimen Stock

  0.65ETON Eton PharmaceuticalsPairCorr
  0.61LLY Eli LillyPairCorr
  0.59IVA Inventiva SaPairCorr
  0.57VIGL Vigil NeurosciencePairCorr
  0.53MGTX MeiraGTx Holdings PLC Downward RallyPairCorr
  0.39PBH Prestige Brand HoldingsPairCorr

ISpecimen Stock Highlights

Treasurer, CEORobert Lim
Old NameIspac 1 Ltd
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Diagnostics & Research, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.880.72
Fairly Up
Slightly volatile
Gross Profit Margin0.420.46
Significantly Down
Slightly volatile
Total Current Liabilities8.3 M5.4 M
Way Up
Slightly volatile
Non Current Liabilities Total24.9 K26.2 K
Notably Down
Slightly volatile
Total Assets16.6 M18.2 M
Significantly Down
Slightly volatile
Total Current Assets12.5 M9.5 M
Significantly Up
Slightly volatile
Debt Levels
ISpecimen can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand ISpecimen's financial leverage. It provides some insight into what part of ISpecimen's total assets is financed by creditors.
Liquidity
iSpecimen currently holds 196.24 K in liabilities with Debt to Equity (D/E) ratio of 0.14, which may suggest the company is not taking enough advantage from borrowing. iSpecimen has a current ratio of 13.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ISpecimen's use of debt, we should always consider it together with its cash and equity.

Investments

(6.18 Million)
iSpecimen (ISPC) is traded on NASDAQ Exchange in USA. It is located in 450 Bedford Street, Lexington, MA, United States, 02420 and employs 53 people. ISpecimen is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.29 M. iSpecimen conducts business under Biotechnology sector and is part of Health Care industry. The entity has 962.64 K outstanding shares of which 29.56 K shares are currently shorted by private and institutional investors with about 0.1 trading days to cover. iSpecimen currently holds about 23.69 M in cash with (5.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.67, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ISpecimen Probability Of Bankruptcy
Ownership Allocation
ISpecimen retains 14.5 (percent) of its outstanding shares held by insiders and 3.71 (percent) owned by outside corporations.
Check ISpecimen Ownership Details

ISpecimen Stock Institutional Holders

InstituionRecorded OnShares
Fny Investment Advisers, Llc2024-12-31
0.0
Vanguard Group Inc2024-09-30
0.0
Geode Capital Management, Llc2024-09-30
0.0
Main Street Financial Solutions, Llc (pa)2024-09-30
0.0
Virtu Financial Llc2024-09-30
0.0
Hrt Financial Llc2024-09-30
0.0
Bridgeway Capital Management, Llc2024-12-31
21.8 K
Ubs Group Ag2024-12-31
11 K
Blackrock Inc2024-12-31
2.8 K
Tower Research Capital Llc2024-12-31
131
Bank Of America Corp2024-12-31
7.0
View ISpecimen Diagnostics

ISpecimen Historical Income Statement

At present, ISpecimen's Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Depreciation And Amortization is expected to grow to about 2.5 M, whereas Interest Expense is forecasted to decline to about 197.3 K. View More Fundamentals

ISpecimen Stock Against Markets

ISpecimen Corporate Management

When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iSpecimen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.12)
Revenue Per Share
19.19
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.44)
Return On Equity
(1.09)
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.